Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Strahlentherapie und Onkologie"
DOI: 10.1007/s00066-017-1196-8
Abstract: AimRetrospective Investigation of the prognostic relevance of clinicopathologic parameters in patients with salivary duct carcinoma (SDC).MethodsAn experienced pathologist reviewed 67 patients with de novo SDC or SDC ex pleomorphic adenoma. Paraffin-embedded tumor samples were examined by… read more here.
Keywords: her2 neu; dmfs; sdc; radiotherapy ... See more keywords
212Pb-conjugated anti-rat HER2/neu antibody against a neu-N derived murine mammary carcinoma cell line: cell kill and RBE in vitro.
Sign Up to like & getrecommendations! Published in 2022 at "International journal of radiation biology"
DOI: 10.1080/09553002.2022.2033341
Abstract: Purpose In the current work, the RBE of a 212Pb conjugated anti-HER2/neu antibody construct has been evaluated, in vitro, by colony formation assay. The RBE was estimated by comparing two absorbed dose-survival curves: the first… read more here.
Keywords: neu antibody; her2 neu; antibody; 212pb conjugated ... See more keywords
Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu expressing breast cancer patients
Sign Up to like & getrecommendations! Published in 2022 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000001521
Abstract: Supplemental Digital Content is available in the text. Introduction Receptors on breast cancer cells play a crucial role in the management of patients. Trastuzumab is a widely used drug for the treatment of HER2/neu expressing… read more here.
Keywords: fab nota; trastuzumab fab; fab; breast cancer ... See more keywords
A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.4030
Abstract: 4030 Background: Gastric cancer is the 5th most common cancer and the 3rd leading cause of cancer deaths. HER2/neu is overexpressed in 15% - 25% of patients with gastric cancer. Monoclonal antibodies against HER2/neu are… read more here.
Keywords: her2 neu; patients her2; imu 131; cancer ... See more keywords
Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model
Sign Up to like & getrecommendations! Published in 2017 at "PLoS ONE"
DOI: 10.1371/journal.pone.0185099
Abstract: One of the challenging issues in vaccine development is peptide and adjuvant delivery into target cells. In this study, we developed a vaccine and therapeutic delivery system to increase cytotoxic T lymphocyte (CTL) response against… read more here.
Keywords: dope; her2 neu; gp2; dope mpl ... See more keywords
Human Tumor Targeted Cytotoxic Mast Cells for Cancer Immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.871390
Abstract: The diversity of autologous cells being used and investigated for cancer therapy continues to increase. Mast cells (MCs) are tissue cells that contain a unique set of anti-cancer mediators and are found in and around… read more here.
Keywords: tumor cells; mcs; mast cells; tumor ... See more keywords
Factors Influencing Lymph Node Positivity in HER2/neu+ Breast Cancer Patients
Sign Up to like & getrecommendations! Published in 2023 at "Current Oncology"
DOI: 10.3390/curroncol30030215
Abstract: Axillary lymph node metastases are a key prognostic factor in breast cancer treatment. Our aim was to evaluate how tumor size, tumor location, and imaging results correlate to axillary lymph node diseases for patients with… read more here.
Keywords: breast cancer; breast; neu breast; her2 neu ... See more keywords
HER2/neu Oncogene Silencing in a Breast Cancer Cell Model Using Cationic Lipid-Based Delivery Systems
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics15041190
Abstract: The overexpression of the human epidermal growth factor 2 (HER2/neu) oncogene is predictive of adverse breast cancer prognosis. Silencing the HER2/neu overexpression using siRNA may be an effective treatment strategy. Major requirements for siRNA-based therapy… read more here.
Keywords: breast cancer; delivery; neu oncogene; her2 neu ... See more keywords
Histone deacetylase inhibitors alter the expression of molecular markers in breast cancer cells via microRNAs.
Sign Up to like & getrecommendations! Published in 2018 at "International journal of molecular medicine"
DOI: 10.3892/ijmm.2018.3616
Abstract: Histone deacetylase inhibitors (HDACis) are able to suppress breast cancer cells in vitro and in vivo by altering the expression of estrogen receptor (ER), progesterone receptor (PR) or human epidermal growth factor receptor 2 (Her2/neu). Since HDACis can alter the expression of… read more here.
Keywords: her2 neu; bt474 cells; breast cancer; saha ... See more keywords
Effect of HER2 and Fascin expression on muscle-invasive bladder cancers: Classification by basaloid and luminal phenotypes
Sign Up to like & getrecommendations! Published in 2022 at "Indian Journal of Pathology and Microbiology"
DOI: 10.4103/ijpm.ijpm_537_21
Abstract: Purpose: The present study aims to identify basaloid and luminal molecular groups and the p53-like sub-group, which is a sub-group of the luminal group, using a specific immunohistochemical panel and investigate human epithelial growth factor… read more here.
Keywords: p53 like; sub; expression; group ... See more keywords
Assessment of topoisomerase II-alpha gene status by dual color chromogenic in situ hybridization in a set of Iraqi patients with invasive breast carcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Indian Journal of Pathology and Microbiology"
DOI: 10.4103/ijpm.ijpm_62_16
Abstract: Background: The human epidermal growth factor receptor 2(HER2) proto-oncogene is overexpressed or amplified in approximately 15%–25% of invasive breast cancers. Approximately 35% of HER2-amplified breast cancers have coamplification of the topoisomerase II-alpha (TOP2A) gene encoding… read more here.
Keywords: status; breast; her2 neu; receptor ... See more keywords